Menu
← Oncology Approval Tracker
FDA DECISION ·
Ziihera
zanidatamab-hrii · Jazz Pharmaceuticals
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with previously treated, unresectable or metastatic biliary tract cancer that is HER2 IHC 3+ on an FDA-approved test.
LAMPGEN ANALYSIS
Why it matters
The first 2024 Ziihera indication provided HER2-directed treatment for a narrowly defined biliary population.
What research teams should watch
Capture the exact HER2 IHC score and prior treatment; set up cardiac assessment and infusion reaction response.
PRIMARY RECORDS